A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Univ Rochester Med Ctr /ID# 130011, Rochester

Georgetown University Hospital /ID# 127261, Washington D.C.

Emory Midtown Infectious Disease Clinic /ID# 131249, Atlanta

The Ohio State University /ID# 127263, Columbus

University of Texas MD Anderson Cancer Center /ID# 126498, Houston

University of California, Los Angeles /ID# 127262, Los Angeles

Moores Cancer Center at UC San Diego /ID# 128535, La Jolla

Stanford University School of Med /ID# 126495, Stanford

Northwestern University Feinberg School of Medicine /ID# 126497, Chicago

Beth Israel Deaconess Medical Center /ID# 134509, Boston

Dana-Farber Cancer Institute /ID# 126496, Boston

Columbia Univ Medical Center /ID# 128536, New York

New York Presbyterian Hospital Weill Cornell Medical Center /ID# 129648, New York

University of Pennsylvania /ID# 126860, Philadelphia

University of Utah /ID# 130813, Salt Lake City